Titlebook: Resistance to Molecular Therapies for Hepatocellular Carcinoma; Augusto Villanueva Book 2017 Springer International Publishing AG 2017 Can

只看該作者 · 發(fā)表于 2025-3-25 10:49:39

Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma,ival and delay of radiologic tumor progression. These benefits were demonstrated in the absence of a high rate of overall response and the magnitude of this improvement varies considerably from patient to patient. Several hypotheses have tried to address the reason for this variability, giving birth

只看該作者 · 發(fā)表于 2025-3-25 14:20:13

只看該作者 · 發(fā)表于 2025-3-25 16:14:18

只看該作者 · 發(fā)表于 2025-3-25 23:37:21

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma,an now be easily tracked, which will provide novel insights into cancer evolution and mechanisms of treatment resistance. This will be critical to provide novel therapeutic targets for second and third line therapies in hepatocellular carcinoma.

只看該作者 · 發(fā)表于 2025-3-26 03:38:44

只看該作者 · 發(fā)表于 2025-3-26 06:33:25

Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance,omote resistance. Understanding the interactions of the components of the liver tumor microenvironment with cancer cells will be critical to design strategies to overcome resistance and improve the therapeutic efficacy of current and future therapies.

只看該作者 · 發(fā)表于 2025-3-26 11:56:25

只看該作者 · 發(fā)表于 2025-3-26 14:26:43

只看該作者 · 發(fā)表于 2025-3-26 19:36:41

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛(ài)論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評(píng)	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 21:21
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved